NGS-based BRCA1/2 mutation testing of high-grade serous ovarian cancer tissue: results and conclusions of the first international round robin trial. (Q48842485)

From Wikidata

Jump to navigation Jump to search

scientific article published on 22 March 2016

Language	Label	Description	Also known as
English	NGS-based BRCA1/2 mutation testing of high-grade serous ovarian cancer tissue: results and conclusions of the first international round robin trial.	scientific article published on 22 March 2016

Statements

scholarly article

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/27003155

NGS-based BRCA1/2 mutation testing of high-grade serous ovarian cancer tissue: results and conclusions of the first international round robin trial. (English)

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/27003155

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

17

object named as

Manfred Dietel

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/27003155

18

object named as

Wilko Weichert

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/27003155

author name string

Volker Endris

1

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/27003155

Albrecht Stenzinger

2

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/27003155

Nicole Pfarr

3

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/27003155

Roland Penzel

4

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/27003155

Markus Möbs

5

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/27003155

Dido Lenze

6

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/27003155

Silvia Darb-Esfahani

7

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/27003155

Michael Hummel

8

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/27003155

Sabine-Merkelbach-Bruse

9

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/27003155

Andreas Jung

10

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/27003155

Ulrich Lehmann

11

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/27003155

Hans Kreipe

12

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/27003155

Thomas Kirchner

13

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/27003155

Reinhard Büttner

14

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/27003155

Wolfram Jochum

15

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/27003155

Gerald Höfler

16

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/27003155

Peter Schirmacher

19

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/27003155

publication date

22 March 2016

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/27003155

Virchows Archiv

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/27003155

468

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/27003155

6

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/27003155

697-705

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/27003155

https://scigraph.springernature.com/pub.10.1007/s00428-016-1919-8

0 references

Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1919-8

21 January 2018

Toward the development of a universal grading system for ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up.

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1919-8

21 January 2018

Reproducibility and prognostic value of histologic type and grade in early epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1919-8

21 January 2018

Early events in the pathogenesis of epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1919-8

21 January 2018

Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1919-8

21 January 2018

Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1919-8

21 January 2018

Survival after recurrence in early-stage high-risk epithelial ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1919-8

21 January 2018

BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1919-8

21 January 2018

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1919-8

21 January 2018

Next-Generation Sequencing in Clinical Molecular Diagnostics of Cancer: Advantages and Challenges

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1919-8

21 January 2018

Clinical applications of next generation sequencing in cancer: from panels, to exomes, to genomes.

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1919-8

21 January 2018

Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1919-8

21 January 2018

Accuracy of BRCA1 and BRCA2 founder mutation analysis in formalin-fixed and paraffin-embedded (FFPE) tissue.

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1919-8

21 January 2018

A reliable method for the detection of BRCA1 and BRCA2 mutations in fixed tumour tissue utilising multiplex PCR-based targeted next generation sequencing

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1919-8

21 January 2018

Molecular diagnostic profiling of lung cancer specimens with a semiconductor-based massive parallel sequencing approach: feasibility, costs, and performance compared with conventional sequencing

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1919-8

21 January 2018

Semiconductor-based sequencing of formalin-fixed, paraffin-embedded colorectal cancer samples

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1919-8

21 January 2018

Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1919-8

21 January 2018

The molecular analysis of BRCA1 and BRCA2: Next-generation sequencing supersedes conventional approaches

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1919-8

21 January 2018

Detection of BRCA1 and BRCA2 germline mutations in Japanese population using next-generation sequencing

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1919-8

21 January 2018

Next-generation sequencing of the BRCA1 and BRCA2 genes for the genetic diagnostics of hereditary breast and/or ovarian cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1919-8

21 January 2018

Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1919-8

21 January 2018

Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1919-8

21 January 2018

Initial Results of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer and Lynch Syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/27003155

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Grading ovarian tumors. Evaluation of decision making by different pathologists.

1 reference

https://pubmed.ncbi.nlm.nih.gov/27003155

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-throughput diagnostic profiling of clinically actionable gene fusions in lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/27003155

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00428-016-1919-8

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/27003155

1 reference

Europe PubMed Central

16 February 2018

http://europepmc.org/abstract/MED/27003155

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48842485&oldid=1650664009"